ReviR Therapeutics Announces First Participant Dosed in Phase 1 Study and Secures CDE Clearance for Two Orphan Indications in China, Supporting Future U.S. Expansion Strategy
Milestone marks the first clinical program for Charcot-Marie-Tooth disease and Vanishing White Matter disease. SAN FRANCISCO and SHANGHAI, March 2, 2026 /PRNewswire/ -- ReviR Therapeutics, a clinical-stage biotechnology company pioneering AI-driven...
ReviR Therapeutics Receives $4.6 Million CIRM Grant to Advance Huntington's Disease Treatment and Announces Key Development Milestone
BRISBANE, Calif., Nov. 20, 2025 /PRNewswire/ -- ReviR Therapeutics, a biotech company focused on developing innovative treatments for neurogenetic diseases, announced today that it has been awarded a $4.6M grant from the California Institute for...
Gastops Receives Investment from RTX for Next Generation Monitoring Technologies
Investment made possible by Canadian Industrial and Technological Benefits Policy (ITB) OTTAWA, ON, May 29, 2025 /PRNewswire/ -- Gastops Ltd. is announcing a joint agreement under Canada's Industrial and Technology Benefits (ITB) policy for a...